<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Health and Nutrition ClusterInstitute of Development StudiesBrightonUK[15], European Commission Directorate" exact="General" post="for Civil Protection and Humanitarian Aid OperationsKinshasaDemocratic Republic of"/>
 <result pre="See: http://creativecommons.org/licenses/by-nc/4.0/.bmjgh-2020-003098.pdf Abstract It is very exceptional that a new" exact="disease" post="becomes a true pandemic. Since its emergence in Wuhan,"/>
 <result pre="Since its emergence in Wuhan, China, in late 2019, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes"/>
 <result pre="its emergence in Wuhan, China, in late 2019, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19,"/>
 <result pre="emergence in Wuhan, China, in late 2019, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has"/>
 <result pre="these different COVID-19 epidemics; by comparing COVID-19 epidemics with other" exact="respiratory" post="diseases, including other coronaviruses that circulate continuously; and by"/>
 <result pre="COVID-19 and for future waves elsewhere. public health Summary box" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that"/>
 <result pre="and for future waves elsewhere. public health Summary box Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes"/>
 <result pre="for future waves elsewhere. public health Summary box Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19,"/>
 <result pre="future waves elsewhere. public health Summary box Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has"/>
 <result pre="only a few months. It is unique that an emerging" exact="respiratory" post="virus becomes a pandemic, and can continue human-to-human transmission"/>
 <result pre="affected countries. This is in fact the case with most" exact="infectious diseases." post="Despite limited initial knowledge on COVID-19, most societies have"/>
 <result pre="is in fact the case with most infectious diseases. Despite" exact="limited" post="initial knowledge on COVID-19, most societies have deployed draconian"/>
 <result pre="responses to, COVID-19. Introduction Late in 2019, a cluster of" exact="acute" post="respiratory disease in Wuhan, China, was attributed to a"/>
 <result pre="to, COVID-19. Introduction Late in 2019, a cluster of acute" exact="respiratory" post="disease in Wuhan, China, was attributed to a new"/>
 <result pre="COVID-19. Introduction Late in 2019, a cluster of acute respiratory" exact="disease" post="in Wuhan, China, was attributed to a new coronavirus,1–3"/>
 <result pre="China, was attributed to a new coronavirus,1–3 later named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2).4 It was soon discovered"/>
 <result pre="was attributed to a new coronavirus,1–3 later named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2).4 It was soon discovered that"/>
 <result pre="attributed to a new coronavirus,1–3 later named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2).4 It was soon discovered that the"/>
 <result pre="discovered that the virus is easily transmitted, can cause severe" exact="disease" post="and can be quite lethal especially in the elderly"/>
 <result pre="in the elderly and those with comorbidities.5–8 The new human" exact="disease" post="is called COVID-19.9 Soon it became clear that its"/>
 <result pre="December 2019–May 2020 Month Key events December 2019 Clusters of" exact="pneumonia" post="of unknown origin in Wuhan, China. Human infection probably"/>
 <result pre="Clusters of pneumonia of unknown origin in Wuhan, China. Human" exact="infection" post="probably began sometime between 9 October and 20 December"/>
 <result pre="series of lockdowns across the world. February 2020 The new" exact="disease" post="named COVID-19 on 11 February 2020. Cruise ship Princess"/>
 <result pre="Cruise ship Princess Diamond quarantined near Japan, sparking media attention." exact="Epidemic" post="in China peaked with ~80 000 cases and 2900"/>
 <result pre="2900 deaths (80% of cases restricted to the Hubei Province).73" exact="Local" post="epidemics of varying attack rates and case fatality rates"/>
 <result pre="China partially lifted lockdown while India instituted the world’s biggest" exact="complete" post="lockdown affecting ~1.4 billion people.74 April 2020 COVID-19 cases"/>
 <result pre="Europe. In Africa, the number of cases seemed to fall" exact="short" post="of forecasts. Tremendous socioeconomic fallouts after an estimated 4.5"/>
 <result pre="compare these knowns with what is known of some other" exact="viral" post="respiratory pathogens and identify the critical unknowns. We also"/>
 <result pre="these knowns with what is known of some other viral" exact="respiratory" post="pathogens and identify the critical unknowns. We also discuss"/>
 <result pre="slowly. In contrast, the collateral effects of a lockdown, even" exact="partial" post="in many cases, are mostly felt by the urban"/>
 <result pre="2. Table 2 Contextual variables potentially influencing transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2 Variable Elements Range (variation/extremes) Population"/>
 <result pre="Table 2 Contextual variables potentially influencing transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2 Variable Elements Range (variation/extremes) Population density"/>
 <result pre="2 Contextual variables potentially influencing transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2 Variable Elements Range (variation/extremes) Population density People"/>
 <result pre="from other viruses We do not attempt to give a" exact="complete" post="overview of viruses but select only those viruses that"/>
 <result pre="or that are closely related such as other coronaviruses. Emerging" exact="viral" post="respiratory pathogens Respiratory viruses such as severe acute respiratory"/>
 <result pre="that are closely related such as other coronaviruses. Emerging viral" exact="respiratory" post="pathogens Respiratory viruses such as severe acute respiratory syndrome"/>
 <result pre="closely related such as other coronaviruses. Emerging viral respiratory pathogens" exact="Respiratory" post="viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV),"/>
 <result pre="coronaviruses. Emerging viral respiratory pathogens Respiratory viruses such as severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus"/>
 <result pre="Emerging viral respiratory pathogens Respiratory viruses such as severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
 <result pre="viral respiratory pathogens Respiratory viruses such as severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and"/>
 <result pre="such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and avian influenza A and also"/>
 <result pre="as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and avian influenza A and also Ebola"/>
 <result pre="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and" exact="avian influenza" post="A and also Ebola have originated from animal hosts"/>
 <result pre="to another animal host. Table 3 Examples of emerging human" exact="respiratory" post="viral diseases without sustained human-to-human transmission Virus Originating animal"/>
 <result pre="another animal host. Table 3 Examples of emerging human respiratory" exact="viral" post="diseases without sustained human-to-human transmission Virus Originating animal host"/>
 <result pre="Bat First emerged in China in November 2002.76 Causes severe" exact="acute" post="respiratory syndrome (SARS). Transmission through superspreading events in healthcare"/>
 <result pre="First emerged in China in November 2002.76 Causes severe acute" exact="respiratory" post="syndrome (SARS). Transmission through superspreading events in healthcare facilities.77"/>
 <result pre="emerged in China in November 2002.76 Causes severe acute respiratory" exact="syndrome" post="(SARS). Transmission through superspreading events in healthcare facilities.77 8422"/>
 <result pre="emerged in the Middle East in 2012.79 Causes Middle East" exact="respiratory" post="syndrome (MERS). Outbreaks from 2012 to 2019 in Saudi"/>
 <result pre="in the Middle East in 2012.79 Causes Middle East respiratory" exact="syndrome" post="(MERS). Outbreaks from 2012 to 2019 in Saudi Arabia"/>
 <result pre="one outbreak in South Korea (2015). 2502 cases; CFR: 34%79" exact="Avian" post="influenza A (H5N1 and H7N9) Birds/poultry Subtypes of influenza"/>
 <result pre="CFR, case fatality rates. The first human case of a" exact="disease" post="from an emerging viral pathogen, the ‘index case’ or"/>
 <result pre="The first human case of a disease from an emerging" exact="viral" post="pathogen, the ‘index case’ or ‘patient zero’, is invariably"/>
 <result pre="and the outbreak stops. Only very exceptionally can a new" exact="viral" post="pathogen sustain continuous human-to-human transmission. Other viral diseases such"/>
 <result pre="can a new viral pathogen sustain continuous human-to-human transmission. Other" exact="viral" post="diseases such as measles and influenza are ‘old’ diseases;"/>
 <result pre="pathogen sustain continuous human-to-human transmission. Other viral diseases such as" exact="measles" post="and influenza are ‘old’ diseases; they have been studied"/>
 <result pre="and influenza: the importance of context It is thought that" exact="measles" post="emerged thousands of years ago in the Middle East."/>
 <result pre="cross-over occurred from the rinderpest virus,31 to become the human" exact="measles" post="virus. Measles has since spread around the globe in"/>
 <result pre="human-to-human transmission. When measles, along with other viruses such as" exact="smallpox" post="and influenza, was introduced in the Americas by European"/>
 <result pre="High mortality, especially in younger persons (5–15 years; ~25% of" exact="total" post="deaths) in the 1918 pandemic, may have been due"/>
 <result pre="estimated CFR&amp;lt;0.1%.85 86 During the 2009 pandemic, mortality was much" exact="lower" post="than in the 1918 pandemic. Higher mortality in persons"/>
 <result pre="integrated with circulating strains of influenza and continues to cause" exact="localised" post="seasonal influenza outbreaks worldwide.88 A major difference between COVID-19"/>
 <result pre="has triggered an immune response in over 5 million confirmed" exact="infections" post="(and probably in many more), definitely too few to"/>
 <result pre=" A dominant way of studying the transmission dynamics of an" exact="infectious disease" post="such as COVID-19, and predicting the amplitude and peak"/>
 <result pre="dominant way of studying the transmission dynamics of an infectious" exact="disease" post="such as COVID-19, and predicting the amplitude and peak"/>
 <result pre="plausible possibilities, between ‘worst-case’ and ‘best-case’ scenarios.  With a new" exact="disease" post="such as COVID-19, certainly at the start of the"/>
 <result pre="the outbreak, the parameters had to be based on very" exact="limited" post="data from a particular context. However, many variables can"/>
 <result pre="unknowns about COVID-19, as of May 2020 Factor Available information" exact="Disease" post="spectrum Many different estimates: Initially, it was estimated that"/>
 <result pre="for remaining totally asymptomatic (estimated 5%–80%93–96). What determines that an" exact="infection" post="remains asymptomatic? Quasi-absence of disease in children: why? Case"/>
 <result pre="5%–80%93–96). What determines that an infection remains asymptomatic? Quasi-absence of" exact="disease" post="in children: why? Case fatality rate (CFR) Initial estimates"/>
 <result pre="influenza 0.1%; common cold: 0%; SARS: 9%–10%; MERS: 30%.97 Calculated" exact="infection" post="fatality rates (cIFR) and calculated CFR (cCFR) on the"/>
 <result pre="treatment, mainly oxygen therapy.100 101 Also, as in certain other" exact="viral" post="diseases such as measles, possibly influenced by the dose"/>
 <result pre="measles, possibly influenced by the dose of virus in initial" exact="infectious" post="inoculum (see Box 3). CFR and IFR vary depending"/>
 <result pre="ventilation, requiring sophisticated equipment and highly skilled personnel. Like COVID-19," exact="measles" post="and influenza have different epidemic patterns in different contexts."/>
 <result pre="different contexts. This also is the case for cholera, tuberculosis," exact="HIV/AIDS" post="and most infectious diseases. The difference in patterns is"/>
 <result pre="also is the case for cholera, tuberculosis, HIV/AIDS and most" exact="infectious diseases." post="The difference in patterns is most pronounced and so"/>
 <result pre="and so is easily understood with vector-borne and water-borne diseases." exact="Epidemic" post="patterns are also different for air-borne infections, although they"/>
 <result pre="air-borne infections, although they are less easily understood. Transmission of" exact="respiratory" post="viruses is influenced by factors related to the virus"/>
 <result pre="Table 4 Factors related to transmission patterns and severity of" exact="respiratory" post="viruses Factor Variables Virus Infection efficiency, transmissibility. Capacity to"/>
 <result pre="transmission patterns and severity of respiratory viruses Factor Variables Virus" exact="Infection" post="efficiency, transmissibility. Capacity to survive outside the human body"/>
 <result pre="(including in aerosols, in droplets, on surfaces, in stools, in" exact="intermediate" post="animal hosts, etc.) Potential to shed virus from an"/>
 <result pre="Genetic stability or variability (affecting the potential of long-lasting immunity)." exact="Viral" post="load determines the incubation period with the formula high"/>
 <result pre="high load -&amp;gt;short incubation period -&amp;gt;high severity. Human host Human" exact="susceptibility to" post="the virus; transfer of parental immunity to newborns. Route"/>
 <result pre="duration of the disease: proportion symptomatic, lethality (CFR). Pathogenicity and" exact="disease" post="spectrum; disease pattern according to age and comorbidities, and"/>
 <result pre="the disease: proportion symptomatic, lethality (CFR). Pathogenicity and disease spectrum;" exact="disease" post="pattern according to age and comorbidities, and related potential"/>
 <result pre="of vaccines, has been well described. Measles is mostly a" exact="childhood" post="disease, but this is not the case in very"/>
 <result pre="this is not the case in very remote communities, where" exact="measles" post="transmission had been interrupted for extended periods (such as"/>
 <result pre="epidemic’.40 41 The latest stages of the global dissemination of" exact="measles" post="have been well documented, including in Australia, the Fiji"/>
 <result pre="occurred in the 19th and the mid-20th centuries.32 42 Fortunately," exact="measles" post="infection creates robust protective immunity and after a first"/>
 <result pre="in the 19th and the mid-20th centuries.32 42 Fortunately, measles" exact="infection" post="creates robust protective immunity and after a first wave"/>
 <result pre="protective immunity and after a first wave becomes a typical" exact="childhood" post="disease, affecting only those without any prior immunity.43 Human-to-human"/>
 <result pre="affecting only those without any prior immunity.43 Human-to-human transmission of" exact="measles" post="virus in a community stops when the virus cannot"/>
 <result pre="the so-called herd immunity is reached.44 45 But transmission of" exact="measles" post="continues elsewhere on the planet from where it can"/>
 <result pre="enough to allow human-to-human transmission again. The epidemic patterns of" exact="measles" post="are easily understood as measles is highly infectious, creates"/>
 <result pre="again. The epidemic patterns of measles are easily understood as" exact="measles" post="is highly infectious, creates disease in almost every infected"/>
 <result pre="measles are easily understood as measles is highly infectious, creates" exact="disease" post="in almost every infected person and leaves lifelong natural"/>
 <result pre="groups in the Sahel), causing epidemics among all those without" exact="acquired" post="immunity and having lost maternal antibodies.46 These diverse patterns"/>
 <result pre="immunity and having lost maternal antibodies.46 These diverse patterns of" exact="measles" post="epidemics have been fundamentally changed by variable coverage of"/>
 <result pre="measles epidemics have been fundamentally changed by variable coverage of" exact="measles" post="vaccination. They can still help us make sense of"/>
 <result pre="2020. Measles illustrates convincingly that the transmission pattern of a" exact="respiratory" post="virus is strongly influenced by the demographic composition, density"/>
 <result pre="continuous only in some large urban areas. It presents in" exact="short" post="epidemics everywhere else with variable periodicity. This transmission pattern"/>
 <result pre="similar for COVID-19. But it took thousands of years for" exact="measles" post="to reach all human communities while SARS-CoV-2 spread to"/>
 <result pre="spread to all countries in only a few months, despite" exact="measles" post="being much more transmissible than SARS-CoV-2. Factors such as"/>
 <result pre="and continuously circulate and mutate frequently.47 48 They can cause" exact="disease" post="in the same person repeatedly. The typical coronavirus remains"/>
 <result pre="disease in the same person repeatedly. The typical coronavirus remains" exact="localised" post="to the epithelium of the upper respiratory tract, causes"/>
 <result pre="The typical coronavirus remains localised to the epithelium of the" exact="upper" post="respiratory tract, causes mild disease and elicits a poor"/>
 <result pre="typical coronavirus remains localised to the epithelium of the upper" exact="respiratory" post="tract, causes mild disease and elicits a poor immune"/>
 <result pre="to the epithelium of the upper respiratory tract, causes mild" exact="disease" post="and elicits a poor immune response, hence the high"/>
 <result pre="strategies and collective strategies How a virus spreads and its" exact="disease" post="progresses depend not only on the variables described above"/>
 <result pre="the human reactions deployed when people are confronted with a" exact="disease" post="outbreak or the threat of an outbreak. All these"/>
 <result pre="epidemic is not fully characterised by the numbers of known" exact="infections" post="and deaths at the scale of a country. Such"/>
 <result pre="Coping strategies are the actions people and families take when" exact="disease" post="threatens and sickness occurs, including the ways they try"/>
 <result pre="available but also on the understanding and interpretation of the" exact="disease" post="by both the scientific community and the community at"/>
 <result pre="applied and enforced. It clearly had an impact, resulting in" exact="total" post="interruption of transmission locally.54 55 Table 5 Measures recommended"/>
 <result pre="Hand hygiene: handwashing or use of hydroalcoholic solution. Physical distancing." exact="Respiratory" post="etiquette. Masks for infected and symptomatic individuals. Community Mass"/>
 <result pre="hydroalcoholic solution. Physical distancing. Respiratory etiquette. Masks for infected and" exact="symptomatic" post="individuals. Community Mass masking with surgical and/or homemade masks"/>
 <result pre="at first sight seem to reduce transmission opportunities for a" exact="respiratory" post="virus. However, knowledge is lacking about the effectiveness of"/>
 <result pre="consider variable options, public authorities often adopted as ‘blueprint’ with" exact="limited" post="consideration for the socioeconomic context.53 56 The initial lockdown"/>
 <result pre="it became increasingly clear that reaching herd immunity in the" exact="short" post="term was illusive. Most countries thus backed off from"/>
 <result pre="The available information on SARS-CoV-2 and the spectrum of COVID-19" exact="disease" post="is summarised in tables 6 and 7. It is"/>
 <result pre="intensive dissemination. Table 6 Knowns, uncertainties and unknowns about severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), as of May 2020"/>
 <result pre="dissemination. Table 6 Knowns, uncertainties and unknowns about severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), as of May 2020 Factor"/>
 <result pre="Table 6 Knowns, uncertainties and unknowns about severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), as of May 2020 Factor Available"/>
 <result pre="Factor Available information Origin ofSARS-CoV-2 Most probably from bats via" exact="intermediate" post="animal hosts to index case.47 104 All subsequent cases"/>
 <result pre="All subsequent cases resulted from human-to-human transmission. Transmission Mainly through" exact="respiratory" post="droplets from infected persons105; by hands, after contamination at"/>
 <result pre="faecal–oral route108 109; detection in sewage.110–112 Related to peak in" exact="upper" post="respiratory tract viral load prior to symptom onset in"/>
 <result pre="route108 109; detection in sewage.110–112 Related to peak in upper" exact="respiratory" post="tract viral load prior to symptom onset in presymptomatic"/>
 <result pre="detection in sewage.110–112 Related to peak in upper respiratory tract" exact="viral" post="load prior to symptom onset in presymptomatic (paucisymptomatic) persons.106"/>
 <result pre="114 Transmission dynamics in asymptomatic persons not fully elucidated although" exact="viral" post="shedding occurs.115 Influence of climate and/or air pollution on"/>
 <result pre="monoxide, are likely a factor facilitating longevity of virus particles.119" exact="Elevated" post="exposure to common particulate matter can alter host immunity"/>
 <result pre="exposure to common particulate matter can alter host immunity to" exact="respiratory" post="viral infections.119 Immunity—protective antibodies IgM and IgA antibody response"/>
 <result pre="to common particulate matter can alter host immunity to respiratory" exact="viral" post="infections.119 Immunity—protective antibodies IgM and IgA antibody response 5–10"/>
 <result pre="has remained unclear. Rechallenge in rhesus macaques showed immunity post" exact="primary" post="infection.121 How protective immunity after first infection is against"/>
 <result pre="showed immunity post primary infection.121 How protective immunity after first" exact="infection" post="is against subsequent infection with an identical or mutated"/>
 <result pre="infection.121 How protective immunity after first infection is against subsequent" exact="infection" post="with an identical or mutated strain has been uncertain."/>
 <result pre="coronaviruses. Box 3 Relationship between the dose of the initial" exact="infectious" post="inoculum, transmission dynamics and severity of the COVID-19 disease"/>
 <result pre="initial infectious inoculum, transmission dynamics and severity of the COVID-19" exact="disease" post="Hypothesis: The dose of the virus in the initial"/>
 <result pre="the spectrum of the COVID-19 disease. It is plausible that:" exact="Viral" post="dose in inoculum is related to severity of disease."/>
 <result pre="Viral dose in inoculum is related to severity of disease." exact="Severity of" post="disease is related to viral shedding and transmission potential."/>
 <result pre="in inoculum is related to severity of disease. Severity of" exact="disease" post="is related to viral shedding and transmission potential. This"/>
 <result pre="to severity of disease. Severity of disease is related to" exact="viral" post="shedding and transmission potential. This hypothesis plays out potentially"/>
 <result pre="individual level: a person infected with a small dose of" exact="viral" post="inoculum will on average develop milder disease than a"/>
 <result pre="small dose of viral inoculum will on average develop milder" exact="disease" post="than a person infected with a high viral inoculum"/>
 <result pre="develop milder disease than a person infected with a high" exact="viral" post="inoculum and vice versa. At cluster level: a person"/>
 <result pre="and vice versa. At cluster level: a person with asymptomatic" exact="infection" post="or mild disease will on average spread lower doses"/>
 <result pre="At cluster level: a person with asymptomatic infection or mild" exact="disease" post="will on average spread lower doses of virus in"/>
 <result pre="with asymptomatic infection or mild disease will on average spread" exact="lower" post="doses of virus in droplets and aerosols and is"/>
 <result pre="the newly infected person is more likely to have milder" exact="disease" post="than if infected by a severely ill person, who"/>
 <result pre="thing, but how effective it is, is quite another. As" exact="acquired" post="immunity after a natural infection is probably not very"/>
 <result pre="is, is quite another. As acquired immunity after a natural" exact="infection" post="is probably not very robust (table 6), it will"/>
 <result pre="Only once? Or yearly? Will there be any adverse effects?" exact="Acquired" post="immunity is not very strong; hence, what is the"/>
 <result pre="be made mandatory, especially for international travel? LICs/LMICs, low and" exact="lower" post="middle income countries. Regarding the severity of COVID-19, initial"/>
 <result pre="have also lessened. It has progressively become clear that many" exact="infections" post="remain asymptomatic, that severe disease is rare in children"/>
 <result pre="progressively become clear that many infections remain asymptomatic, that severe" exact="disease" post="is rare in children and young adults, and that"/>
 <result pre="of the variables in the transmission of SARS-CoV-2 and the" exact="disease" post="spectrum of COVID-19 could be quantified. This allows for"/>
 <result pre="Predictive models developed by the Imperial College63; the Center for" exact="Disease" post="Dynamics, Economics &amp;amp; Policy and Johns Hopkins University28; the"/>
 <result pre="possible. This will strongly depend on: How strong will the" exact="acquired" post="immunity after a first infection with SARS-CoV-2 be and"/>
 <result pre="on: How strong will the acquired immunity after a first" exact="infection" post="with SARS-CoV-2 be and how long will it last?"/>
 <result pre="SARS-CoV-2 be and how long will it last? Evidence of" exact="acquired" post="immunity against subsequent infections has been limited. Measurable antibodies"/>
 <result pre="long will it last? Evidence of acquired immunity against subsequent" exact="infections" post="has been limited. Measurable antibodies have been observed in"/>
 <result pre="recovered from COVID-19,131 and research in animal models has suggested" exact="limited" post="possibility of reinfection.121 It is still unclear as to"/>
 <result pre="for those recovered from COVID-19 has been ongoing.128 137 How" exact="stable" post="is the virus (mutation) and do the different clades"/>
 <result pre="second and third waves were characterised by a more severe" exact="disease" post="pattern.36 84 What is the role of children in"/>
 <result pre="transmission? Children have quasi-universally presented less severe disease. However, their" exact="susceptibility to" post="infection remains unclear, with large heterogeneity reported between studies.138"/>
 <result pre="have quasi-universally presented less severe disease. However, their susceptibility to" exact="infection" post="remains unclear, with large heterogeneity reported between studies.138 139"/>
 <result pre="where lockdown or more selective measures are equally effective with" exact="lower" post="societal effects. Relationship between the dose of the initial"/>
 <result pre="lower societal effects. Relationship between the dose of the initial" exact="infectious" post="inoculum, transmission dynamics and severity of the COVID-19 disease"/>
 <result pre="initial infectious inoculum, transmission dynamics and severity of the COVID-19" exact="disease" post="New evidence is being discovered rapidly. Some evidence comes"/>
 <result pre="is a relationship between the dose of virus in the" exact="infectious" post="inoculum and the severity of COVID-19 disease. Several intriguing"/>
 <result pre="to create new insight which may influence control strategies. This" exact="viral" post="inoculum theory is consistent with many observations from the"/>
 <result pre="in subsequent waves. In some countries, transmission will continue at" exact="lower" post="levels. In other countries, such as China, the virus"/>
 <result pre="hotter climates the transmission may become continuous, year round at" exact="lower" post="levels. It is increasingly clear that hot climate does"/>
 <result pre="immunity. Individual immunity will dictate how mild or severe the" exact="disease" post="will be in subsequent infections. Herd immunity could be"/>
 <result pre="communities/regions/countries that, in theory, could be fenced off, allowing only" exact="limited" post="interaction with other areas, impacting the spread of the"/>
 <result pre="scale? Conclusion The current first wave is unfolding in the" exact="absence of" post="effective biomedical tools (no vaccine, no effective antiviral or"/>
 <result pre="thankful to Mrs. Ann Byers for editing the manuscript at" exact="short" post="notice. Twitter: @Ingelbeen, @jdossou80, @seyeabimbola, @jarthurk, @@vdbrouwere, @SamehAlawlaqi, @prashanthns"/>
 <result pre="additional data are available. References References 1LuH, StrattonCW, TangYi‐WeiOutbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
 <result pre="and the miracle. J Med Virol2020;92:401–2. 10.1002/jmv.2567831950516 2XinhuanetNew-type coronavirus causes" exact="pneumonia" post="in Wuhan: expert; 9 January 2020, 2020 Available: http://www.xinhuanet.com/english/2020-01/09/c_138690570.htm"/>
 <result pre="3ZhuN, ZhangD, WangW, et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med Overseas Ed2020;382:727–33."/>
 <result pre="of the International Committee on Taxonomy of VirusesThe species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2."/>
 <result pre="the International Committee on Taxonomy of VirusesThe species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat"/>
 <result pre="5XuZ, ShiL, WangY, et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP,"/>
 <result pre="ShiL, WangY, et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP, FanY,"/>
 <result pre="Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP, FanY, et al.The clinical characteristics of" exact="pneumonia" post="patients coinfected with 2019 novel coronavirus and influenza virus"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–Infected" exact="pneumonia" post="in Wuhan, China. JAMA2020;323:106110.1001/jama.2020.1585 8LiQ, GuanX, WuP, et al.Early"/>
 <result pre="Med Overseas Ed2020;382:1199–207. 10.1056/NEJMoa2001316 9collab: World Health OrganizationNaming the coronavirus" exact="disease" post="(COVID-19) and the virus that causes it, 2020 Available:"/>
 <result pre="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 [Accessed 17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="[Accessed 17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
 <result pre="17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
 <result pre="World Health OrganizationReport of the WHO-China joint mission on coronavirus" exact="disease" post="2019 (COVID-19), 2020 Available: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf [Accessed 14 May 2020]."/>
 <result pre="14 May 2020]. 15DanisK, EpaulardO, BénetT, et al.Cluster of coronavirus" exact="disease" post="2019 (Covid-19) in the French Alps, 2020. Clin Infect"/>
 <result pre="a COVID-19 outbreak in Germany resulting from a single travel-associated" exact="primary" post="case: a case series. Lancet Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS,"/>
 <result pre="case series. Lancet Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS, KokK-H, et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS, KokK-H, et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="Available: https://ourworldindata.org/grapher/total-confirmed-cases-of-covid-19-per-million-people-vs-gdp-per-capita [Accessed 1 Jul 2020]. 28collab: The Center For" exact="Disease" post="Dynamics Economics &amp;amp; PolicyModeling the spread and prevention of"/>
 <result pre="and the world. Respirology2003;8 Suppl:S2–5. 10.1046/j.1440-1843.2003.00516.x15018125 31FuruseY, SuzukiA, OshitaniHOrigin of" exact="measles" post="virus: divergence from rinderpest virus between the 11th and"/>
 <result pre="protective immunity. Lancet2020;395:1527–9. 10.1016/S0140-6736(20)30985-532353328 38PanumPLObservations made during the epidemic of" exact="measles" post="on the Faroe Islands in the year 1846. New"/>
 <result pre="York: Delta Omega Society, 1940. 39RhodesCJ, AndersonRMA scaling analysis of" exact="measles" post="epidemics in a small population. Philos Trans R Soc"/>
 <result pre="WatmoughJReproduction numbers and sub-threshold endemic equilibria for compartmental models of" exact="disease" post="transmission. Math Biosci2002;180:29–48. 10.1016/S0025-5564(02)00108-612387915 45FineP, EamesK, HeymannDL&quot;Herd Immunity&quot;: A"/>
 <result pre="Biosci2002;180:29–48. 10.1016/S0025-5564(02)00108-612387915 45FineP, EamesK, HeymannDL&quot;Herd Immunity&quot;: A Rough Guide. Clinical" exact="Infectious" post="Diseases2011;52:911–6. 10.1093/cid/cir00721427399 46LoutanL, PaillardSMeasles in a West African nomadic"/>
 <result pre="Guide. Clinical Infectious Diseases2011;52:911–6. 10.1093/cid/cir00721427399 46LoutanL, PaillardSMeasles in a West" exact="African" post="nomadic community. Bull World Health Organ1992;70:741–4.1486670 47Z-WY, YuanS, YuenK-S,"/>
 <result pre="herd immunity. To beat COVID-19, we’ll ultimately need it. National" exact="Geographic" post="2020 20 March, 2020 Available: https://www.nationalgeographic.com/science/2020/03/uk-backed-off-on-herd-immunity-to-beat-coronavirus-we-need-it/ [Accessed 30 May"/>
 <result pre="et al.The potential effects of widespread community transmission of SARS-CoV-2" exact="infection" post="in the world Health organization African region: a predictive"/>
 <result pre="community transmission of SARS-CoV-2 infection in the world Health organization" exact="African" post="region: a predictive model. BMJ Glob Health2020;5:e002647. 10.1136/bmjgh-2020-002647 68Van"/>
 <result pre="December 2019. Int J Antimicrob Agents2020;55:10600610.1016/j.ijantimicag.2020.10600632371096 71collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) - Situation Report – 12; 1 February"/>
 <result pre="Apr 2020]. 72HamblinJA Historic Quarantine: China’s attempt to curb a" exact="viral" post="outbreak is a radical experiment in authoritarian medicine. Atlantic2020."/>
 <result pre="radical experiment in authoritarian medicine. Atlantic2020. 73collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) - Situation Report – 41, 2020 Available:"/>
 <result pre="2003 Available: https://www.who.int/csr/don/2003_07_04/en/ [Accessed 17 Apr 2020]. 77collab: Centers for" exact="Disease" post="Control and PreventionSevere Acute Respiratory Syndrome - Singapore, 2003,"/>
 <result pre="17 Apr 2020]. 77collab: Centers for Disease Control and PreventionSevere" exact="Acute" post="Respiratory Syndrome - Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab:"/>
 <result pre="Apr 2020]. 77collab: Centers for Disease Control and PreventionSevere Acute" exact="Respiratory" post="Syndrome - Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab: World"/>
 <result pre="2020]. 77collab: Centers for Disease Control and PreventionSevere Acute Respiratory" exact="Syndrome" post="- Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab: World Health"/>
 <result pre="Apr 2020]. 81collab: World Health OrganizationWHO Risk Assessment of Human" exact="infections" post="with avian influenza A(H7N9) virus, 2015 Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed"/>
 <result pre="81collab: World Health OrganizationWHO Risk Assessment of Human infections with" exact="avian influenza" post="A(H7N9) virus, 2015 Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed 17 Apr 2020]."/>
 <result pre="Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed 17 Apr 2020]. 82collab: World Health OrganizationHuman" exact="infection" post="with avian influenza A(H5N1) virus - update (9 January"/>
 <result pre="[Accessed 17 Apr 2020]. 82collab: World Health OrganizationHuman infection with" exact="avian influenza" post="A(H5N1) virus - update (9 January 2014), 2014 Available:"/>
 <result pre="ChotpitayasunondhT, et al.Clinical aspects of pandemic 2009 influenza A (H1N1)" exact="virus infection." post="N Engl J Med2010;362:1708–19. 10.1056/NEJMra100044920445182 88collab: World Health OrganizationH1N1"/>
 <result pre="90VerityR, OkellLC, DorigattiI, et al.Estimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysis. Lancet Infect Dis2020;20:669–77. 10.1016/S1473-3099(20)30243-732240634 91collab:"/>
 <result pre="Lancet Infect Dis2020;20:669–77. 10.1016/S1473-3099(20)30243-732240634 91collab: Epidemiology Working Group for NCIP" exact="Epidemic" post="Response - Chinese Center for Disease Control and PreventionEpidemiological"/>
 <result pre="Working Group for NCIP Epidemic Response - Chinese Center for" exact="Disease" post="Control and PreventionEpidemiological analysis of new coronavirus pneumonia. Zhonghua"/>
 <result pre="[Chinese]2020;41:145–51. 92WuZ, McGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (Covid-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72 314 cases from the Chinese center for" exact="disease" post="control and prevention. JAMA2020. [Epub ahead of print: 24"/>
 <result pre="93MizumotoK, KagayaK, ZarebskiA, et al.Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the diamond Princess cruise"/>
 <result pre="SHIP, Yokohama, Japan, 2020. Euro Surveill2020;2510.2807/1560-7917.ES.2020.25.10.2000180 94collab: National Institute of" exact="Infectious" post="Diseases (NIID)Field Briefing: diamond Princess COVID-19 cases, 2020 Available:"/>
 <result pre="Yokohama, Japan, 2020. Euro Surveill2020;2510.2807/1560-7917.ES.2020.25.10.2000180 94collab: National Institute of Infectious" exact="Diseases" post="(NIID)Field Briefing: diamond Princess COVID-19 cases, 2020 Available: https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html"/>
 <result pre="MiyamaT, et al.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19). Int J Infect Dis2020;94:154–5. 10.1016/j.ijid.2020.03.02032179137 96HeneghanC, BrasseyJ, JeffersonT,"/>
 <result pre="BrasseyJ, JeffersonT, collab: Centre for Evidence-Based Medicine, Nuffield Department of" exact="Primary" post="Care Health Sciences, University of OxfordCOVID-19: What proportion are"/>
 <result pre="Engl J Med2020;382:1268–9. 10.1056/NEJMe200238732109011 98RussellTW, HellewellJ, JarvisCI, et al.Estimating the" exact="infection" post="and case fatality ratio for coronavirus disease (COVID-19) using"/>
 <result pre="et al.Estimating the infection and case fatality ratio for coronavirus" exact="disease" post="(COVID-19) using age-adjusted data from the outbreak on the"/>
 <result pre="Mar 310.1053/j.gastro.2020.02.054 109XuY, LiX, ZhuB, et al.Characteristics of pediatric SARS-CoV-2" exact="infection" post="and potential evidence for persistent fecal viral shedding. Nat"/>
 <result pre="of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal" exact="viral" post="shedding. Nat Med2020;26:502–5. 10.1038/s41591-020-0817-432284613 110MedemaG, HeijnenL, ElsingaG, et al.Presence"/>
 <result pre="for the wastewater surveillance of COVID-19 in the community. Sci" exact="Total" post="Environ2020;728:138764. 10.1016/j.scitotenv.2020.13876432387778 112LodderW, de Roda HusmanAMSARS-CoV-2 in wastewater: potential"/>
 <result pre="contact tracing. Science2020;368:eabb693610.1126/science.abb693632234805 115HeX, LauEHY, WuP, et al.Temporal dynamics in" exact="viral" post="shedding and transmissibility of COVID-19. Nat Med2020;26:672–5. 10.1038/s41591-020-0869-532296168 116AraujoMB,"/>
 <result pre="119MartellettiL, MartellettiPAir pollution and the novel Covid-19 disease: a putative" exact="disease" post="risk factor. SN Compr Clin Med2020:1–5. 10.1007/s42399-020-00274-4 120GuoL, RenL,"/>
 <result pre="YangS, et al.Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19). Clin Infect Dis2020;2410.1093/cid/ciaa310 121BaoL, DengW, GaoH, et al.Reinfection"/>
 <result pre="of early SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe" exact="acute" post="respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease"/>
 <result pre="early SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe acute" exact="respiratory" post="syndrome coronavirus 2-specific antibody responses in coronavirus disease patients."/>
 <result pre="SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe acute respiratory" exact="syndrome" post="coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg"/>
 <result pre="al.Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus" exact="disease" post="patients. Emerg Infect Dis2020;26:1478–88. 10.3201/eid2607.20084132267220 126GorseGJ, PatelGB, VitaleJN, et"/>
 <result pre="VitaleJN, et al.Prevalence of antibodies to four human coronaviruses is" exact="lower" post="in nasal secretions than in serum. CVI2010;17:1875–80. 10.1128/CVI.00278-1020943876 127TheelES,"/>
 <result pre="TrapmanP, BallFGThe disease-induced herd immunity level for Covid-19 is substantially" exact="lower" post="than the classical herd immunity level. medRxiv2020. 130GomesMGM, CorderRM,"/>
 <result pre="COVID-19. JAMA2020;323:1406–7. 10.1001/jama.2020.2565 141RotheC, SchunkM, SothmannP, et al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in Germany. N Engl J"/>
</results>
